ORGANIC
LETTERS
2004
Vol. 6, No. 9
1405-1408
Solid-Phase Syntheses of Furopyridine
and Furoquinoline Systems
Pablo Cironi,†,‡,§ Judit Tulla-Puche,†,§, George Barany,
,†,|
,†,‡
Fernando Albericio,* and Mercedes AÄ lvarez*
Biomedical Research Institute, Barcelona Scientific Park,
Laboratory of Organic Chemistry, Faculty of Pharmacy, and
Department of Organic Chemistry, UniVersity of Barcelona, 08028 Barcelona, Spain,
and Department of Chemistry, UniVersity of Minnesota, Minneapolis, Minnesota 55455
Received February 10, 2004
ABSTRACT
Syntheses of 2-substituted furo[3,2-b]pyridines and furo[3,2-h]quinolines have been achieved for the first time in the solid-phase mode. The
central enabling steps involved concomitant deprotection/cyclization promoted by the mild base K2CO . Reactions were monitored “in situ”
3
in real time by a variety of spectroscopic techniques, which allowed full and accurate control of progress in these syntheses.
Completion of the Human Genome Program (HGP) in April
2003, along with accumulating DNA sequence information
from the genomes of an exponentially increasing number of
microbial, plant, or animal species, has led to a correspond-
ingly large number of protein targets that must be matched
with effective and selective organic molecule ligands identi-
fied through high-throughput screening.1 The demand for
potential ligands may best be met by combinatorial synthesis
onto diverse scaffolds, as expedited by a solid-phase mode
(SPOS) that has the advantages of being amenable to
automation and potentially giving products suitable for
further testing without going through time-consuming inter-
mediate purification steps.2
The focus of this report is to describe solid-phase syntheses
of furo[3,2-b]pyridines and furo[3,2-h]quinolines. The former
heterocycle is rarely found in nature,3 yet its heteroaromatic
unit is the nucleus of the pharmacophores of potent HIV
protease inhibitors such as L-754,3944 and PNU-142721.5
The latter tricyclic system has been encountered even fewer
times.6 Precedents for solution syntheses in these families
are relatively sparse,7 and to the best of our knowledge, their
(3) (a) Grundon, M. F. The Alkaloids; Academic Press: New York, 1979;
Vol. 17, pp 105-198. (b) Arruda, M. S. P.; Fernandes, J. B.; Vieira, P. C.;
Da Silva, M. F. D. G. F.; Pirani, J. R. Biochem. Syst. Ecol. 1992, 20, 173-
178.
(4) (a) Houpis, I. N.; Choi, W. B.; Reider, P. J.; Molina, A.; Churchill,
H.; Lynch, J.; Volante, R. P. Tetrahedron Lett. 1994, 35, 9355-9358. (b)
Bhupathy, M.; Conlon, D. A.; Wells, K. M.; Nelson, J. R.; Reider, P. J.;
Rossen, K.; Sager, J. W.; Volante, R. P.; Dorsey, B. D.; Hoffman, J. M.;
Joseph, S. A.; McDaniel, S. L. J. Heterocycl. Chem. 1995, 32, 1283-1287.
(5) (a) Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han,
F.; Watt, W.; Morris, J. J. Org. Chem. 1998, 63, 7851-7859. (b) Wishka,
D. G.; Graber, D. R.; Kopta, L. A.; Olmsted, R. A.; Friis, J. M.; Hosley, J.
D.; Adams, W. J.; Seest, E. P.; Castle, T. M.; Dolak, L. A.; Keiser, B. J.;
Yagi, Y.; Jeganathan, A.; Schlachter, S. T.; Murphy, M. J.; Cleek, G. J.;
Nugent, R. A.; Poppe, S. M.; Swaney, S. M.; Han, F.; Watt, W.; White,
W. L.; Poel, T. J.; Thomas, R. C.; Voorman, R. L.; Stephanski, K. J.; Stehle,
R. G.; Tarpley, W. G.; Morris, J. J. Med. Chem. 1998, 41, 1357-1360. (c)
Uenishi, J.; Takagi, T.; Ueno, T.; Hiraoka, T.; Yonemitsu, O.; Tsukube, H.
Synlett 1999, 1, 41-44.
† Barcelona Scientific Park, University of Barcelona.
‡ Faculty of Pharmacy, University of Barcelona.
§ The first two authors have contributed similarly to the present work.
University of Minnesota.
| Department of Organic Chemistry, University of Barcelona.
(1) Current logic of the drug discovery field was reviewed by: Brein-
bauer, R.; Vetter, I. R.; Waldmann, H. Angew. Chem., Int. Ed. 2002, 41,
2878-2890 and references therein.
(2) For examples of relatively complex natural products that can be
prepared efficiently by SPOS, see: (a) Nicolaou, K. C.; Winssinger, N.;
Pastor, J.; Ninkovic, S.; Sarabia, F.; He, Y.; Vourloumis, D.; Yang, Z.; Li,
T.; Giannakakou, P.; Hamel, E. Nature 1997, 387, 268-272. (b) Myers,
A. G.; Lanman, B. A. J. Am. Chem. Soc. 2002, 124, 12969-12971. (c)
Cironi, P.; Manzanares, I.; Albericio, F.; AÄ lvarez, M. Org. Lett. 2003, 5,
2959-2962.
(6) For examples, see: (a) Beugelmans, R.; Bois-Choussy, M. Hetero-
cycles 1987, 26, 1863-1871 and references therein. (b) Yavari, I.; Anary-
Abbasinejad, M.; Alizadeh, A. Tetrahedron Lett. 2002, 43, 4503-4505.
10.1021/ol049762f CCC: $27.50 © 2004 American Chemical Society
Published on Web 03/26/2004